Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

May

Today In Oncology

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma

Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants

Tiragolumab Plus Atezolizumab and Chemotherapy in Advanced Nonsquamous NSCLC

Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing CRS

High YAP1 Expression Leads to Chemotherapy Resistance Relapse in Treated SCLC